RSLS logo

ReShape Lifesciences (RSLS) EBIT

Annual EBIT

-$14.64 M
+$12.44 M+45.94%

December 31, 2023

Summary

Performance

1-Year Change

+45.94%

3-Year Change

+25.92%

5-Year Change

+62.18%

15-Year Change

+55.34%

RSLS EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

61.23%
RSLS annual earnings before interest & taxes is higher than 61.23% of companies in Healthcare sector

High & Low

All-time High

-$1.90 M

3-Year Low

-$62.59 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
RSLS previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Apr 1, 2025
RSLS next annual earnings announcement is scheduled for Apr 1, 2025

OtherRSLSprofitabilitymetrics:

Annual Revenue

$8.68 M
RSLS annual revenue is $8.68 million

Annual Net Income

-$11.39 M
RSLS annual net profit is -$11.39 million

Annual EBITDA

-$14.48 M
RSLS annual EBITDA is -$14.48 million

Annual EPS

-$110.78
RSLS annual earnings per share is -$110.78

Quarterly EBIT

-$1.76 M
+$293.00 K+14.26%

September 30, 2024

Summary

Performance

3-Month Change

+14.26%

1-Year Change

+43.25%

3-Year Change

+88.25%

5-Year Change

+60.68%

RSLS Quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

67.37%
RSLS quarterly earnings before interest & taxes is higher than 67.37% of companies in Healthcare sector

High & Low

All-time High

-$1.76 M
RSLS quarterly earnings before interest & taxes is currently at an all-time high

3-Year Low

-$41.64 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
RSLS previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Apr 1, 2025
RSLS next earnings announcement is scheduled for Apr 1, 2025

OtherRSLSprofitabilitymetrics:

Quarterly Revenue

$2.29 M
RSLS quarterly revenue is $2.29 million

Quarterly Net Income

-$1.58 M
RSLS quarterly net profit is -$1.58 million

Quarterly EBITDA

-$1.76 M
RSLS quarterly EBITDA is -$1.76 million

Quarterly EPS

-$3.11
RSLS quarterly earnings per share is -$3.11

TTM EBIT

-$7.92 M
+$1.34 M+14.49%

September 30, 2024

Summary

Performance

3-Month Change

+14.49%

1-Year Change

+55.94%

3-Year Change

+74.56%

5-Year Change

+78.52%

RSLS TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

69.55%
RSLS TTM earnings before interest & taxes is higher than 69.55% of companies in Healthcare sector

High & Low

All-time High

-$2.80 M

3-Year Low

-$73.60 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
RSLS previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Apr 1, 2025
RSLS next earnings announcement is scheduled for Apr 1, 2025

OtherRSLSprofitabilitymetrics:

TTM Revenue

$8.18 M
RSLS TTM revenue is $8.18 million

TTM Net Income

-$7.07 M
RSLS TTM net profit is -$7.07 million

TTM EBITDA

-$7.90 M
RSLS TTM EBITDA is -$7.90 million

TTM EPS

-$16.01
RSLS TTM earnings per share is -$16.01

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

Annual EBIT

-$14.64 M
RSLS annual earnings before interest & taxes is -$14.64 million

Annual Revenue

$8.68 M
RSLS annual revenue is $8.68 million

Annual Cost Of Goods Sold

$3.13 M
RSLS annual cost of goods sold is $3.13 million

Annual Operating Expenses

$20.19 M
RSLS annual total operating expenses is $20.19 million

RSLS EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+45.9%+43.3%+55.9%
3 y3 years+25.9%+88.3%+74.6%
5 y5 years+62.2%+60.7%+78.5%

RSLS EBIT Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+76.6%at high+95.8%at high+89.2%
5 y5-yearat high+80.4%at high+95.8%at high+89.4%
alltimeall time-670.1%+80.4%at high+95.8%-182.5%+89.4%

ReShape Lifesciences EBIT History

DateAnnualQuarterlyTTM
Sep 2024
-
-$1.76 M(-14.3%)
-$7.92 M(-14.5%)
Jun 2024
-
-$2.05 M(-7.1%)
-$9.26 M(-17.4%)
Mar 2024
-
-$2.21 M(+16.6%)
-$11.22 M(-23.4%)
Dec 2023
-$14.64 M(-45.9%)
-$1.90 M(-38.9%)
-$14.64 M(-18.6%)
Sep 2023
-
-$3.10 M(-22.6%)
-$17.98 M(-9.0%)
Jun 2023
-
-$4.01 M(-28.8%)
-$19.74 M(-19.7%)
Mar 2023
-
-$5.63 M(+7.6%)
-$24.60 M(-9.2%)
Dec 2022
-$27.08 M(-56.7%)
-$5.23 M(+7.4%)
-$27.08 M(-57.3%)
Sep 2022
-
-$4.87 M(-45.0%)
-$63.49 M(-13.7%)
Jun 2022
-
-$8.86 M(+9.2%)
-$73.60 M(+7.5%)
Mar 2022
-
-$8.11 M(-80.5%)
-$68.44 M(+6.0%)
Dec 2021
-$62.59 M(+216.7%)
-$41.64 M(+177.9%)
-$64.58 M(+107.5%)
Sep 2021
-
-$14.98 M(+304.8%)
-$31.13 M(+50.9%)
Jun 2021
-
-$3.70 M(-12.9%)
-$20.62 M(+4.2%)
Mar 2021
-
-$4.25 M(-48.1%)
-$19.79 M(+0.1%)
Dec 2020
-$19.76 M(-73.5%)
-$8.19 M(+82.9%)
-$19.76 M(-46.4%)
Sep 2020
-
-$4.48 M(+56.3%)
-$36.87 M(-39.6%)
Jun 2020
-
-$2.87 M(-32.2%)
-$61.07 M(-18.0%)
Mar 2020
-
-$4.22 M(-83.3%)
-$74.50 M(-0.2%)
Dec 2019
-$74.65 M(+92.9%)
-$25.30 M(-11.8%)
-$74.65 M(+39.6%)
Sep 2019
-
-$28.68 M(+76.0%)
-$53.48 M(+77.7%)
Jun 2019
-
-$16.29 M(+272.6%)
-$30.09 M(-12.3%)
Mar 2019
-
-$4.37 M(+5.7%)
-$34.32 M(-11.3%)
Dec 2018
-$38.70 M(+18.1%)
-$4.14 M(-21.8%)
-$38.70 M(-10.3%)
Sep 2018
-
-$5.29 M(-74.2%)
-$43.14 M(-9.8%)
Jun 2018
-
-$20.52 M(+134.3%)
-$47.85 M(+40.0%)
Mar 2018
-
-$8.76 M(+2.1%)
-$34.17 M(+4.2%)
Dec 2017
-$32.78 M(+70.2%)
-$8.58 M(-14.2%)
-$32.78 M(+17.4%)
Sep 2017
-
-$9.99 M(+46.1%)
-$27.92 M(+21.1%)
Jun 2017
-
-$6.84 M(-7.1%)
-$23.06 M(+13.2%)
Mar 2017
-
-$7.37 M(+97.8%)
-$20.36 M(+5.8%)
Dec 2016
-$19.26 M(-21.6%)
-$3.72 M(-27.4%)
-$19.26 M(-13.3%)
Sep 2016
-
-$5.13 M(+23.9%)
-$22.20 M(+7.5%)
Jun 2016
-
-$4.14 M(-33.8%)
-$20.66 M(-13.4%)
Mar 2016
-
-$6.26 M(-6.2%)
-$23.86 M(-2.9%)
Dec 2015
-$24.56 M(-4.1%)
-$6.67 M(+86.1%)
-$24.56 M(+2.4%)
Sep 2015
-
-$3.59 M(-51.2%)
-$23.97 M(-7.7%)
Jun 2015
-
-$7.34 M(+5.5%)
-$25.98 M(-0.0%)
Mar 2015
-
-$6.96 M(+14.3%)
-$26.00 M(+1.5%)
Dec 2014
-$25.60 M
-$6.09 M(+8.8%)
-$25.60 M(-1.1%)
DateAnnualQuarterlyTTM
Sep 2014
-
-$5.59 M(-24.0%)
-$25.89 M(-1.8%)
Jun 2014
-
-$7.36 M(+12.1%)
-$26.37 M(+5.1%)
Mar 2014
-
-$6.56 M(+3.0%)
-$25.09 M(+1.0%)
Dec 2013
-$24.85 M(+10.2%)
-$6.37 M(+4.9%)
-$24.85 M(-1.5%)
Sep 2013
-
-$6.08 M(+0.1%)
-$25.24 M(+2.0%)
Jun 2013
-
-$6.08 M(-3.9%)
-$24.74 M(+5.8%)
Mar 2013
-
-$6.32 M(-6.5%)
-$23.39 M(+3.7%)
Dec 2012
-$22.56 M(-10.7%)
-$6.76 M(+21.1%)
-$22.56 M(-4.8%)
Sep 2012
-
-$5.58 M(+18.2%)
-$23.70 M(-6.1%)
Jun 2012
-
-$4.72 M(-13.9%)
-$25.25 M(-2.5%)
Mar 2012
-
-$5.49 M(-30.5%)
-$25.91 M(+2.5%)
Dec 2011
-$25.27 M(+57.1%)
-$7.90 M(+10.8%)
-$25.27 M(+20.9%)
Sep 2011
-
-$7.13 M(+32.6%)
-$20.90 M(+17.0%)
Jun 2011
-
-$5.38 M(+10.8%)
-$17.86 M(+7.6%)
Mar 2011
-
-$4.86 M(+37.5%)
-$16.60 M(+3.2%)
Dec 2010
-$16.09 M(-33.6%)
-$3.53 M(-13.7%)
-$16.09 M(-8.4%)
Sep 2010
-
-$4.09 M(-0.5%)
-$17.57 M(-15.3%)
Jun 2010
-
-$4.11 M(-5.4%)
-$20.74 M(-9.3%)
Mar 2010
-
-$4.35 M(-13.3%)
-$22.86 M(-5.6%)
Dec 2009
-$24.21 M(-33.2%)
-$5.02 M(-31.0%)
-$24.21 M(-5.7%)
Sep 2009
-
-$7.27 M(+16.5%)
-$25.66 M(-9.8%)
Jun 2009
-
-$6.23 M(+9.4%)
-$28.46 M(-14.9%)
Mar 2009
-
-$5.70 M(-11.9%)
-$33.45 M(-7.8%)
Dec 2008
-$36.27 M(+29.4%)
-$6.47 M(-35.7%)
-$36.27 M(-5.7%)
Sep 2008
-
-$10.06 M(-10.4%)
-$38.47 M(+10.4%)
Jun 2008
-
-$11.23 M(+31.8%)
-$34.86 M(+15.3%)
Mar 2008
-
-$8.52 M(-1.8%)
-$30.25 M(+6.7%)
Dec 2007
-$28.03 M(+54.7%)
-$8.67 M(+34.4%)
-$28.34 M(+13.8%)
Sep 2007
-
-$6.45 M(-2.4%)
-$24.90 M(+10.2%)
Jun 2007
-
-$6.61 M(0.0%)
-$22.60 M(+12.2%)
Mar 2007
-
-$6.61 M(+26.5%)
-$20.14 M(+13.9%)
Dec 2006
-$18.12 M(+62.5%)
-$5.22 M(+25.7%)
-$17.69 M(+15.9%)
Sep 2006
-
-$4.16 M(0.0%)
-$15.27 M(+9.7%)
Jun 2006
-
-$4.16 M(0.0%)
-$13.92 M(+10.8%)
Mar 2006
-
-$4.16 M(+48.2%)
-$12.57 M(+12.0%)
Dec 2005
-$11.15 M(+223.4%)
-$2.80 M(0.0%)
-$11.22 M(+33.3%)
Sep 2005
-
-$2.80 M(0.0%)
-$8.41 M(+50.0%)
Jun 2005
-
-$2.80 M(0.0%)
-$5.61 M(+100.0%)
Mar 2005
-
-$2.80 M
-$2.80 M
Dec 2004
-$3.45 M(+81.4%)
-
-
Dec 2003
-$1.90 M
-
-

FAQ

  • What is ReShape Lifesciences annual earnings before interest & taxes?
  • What is the all time high annual EBIT for ReShape Lifesciences?
  • What is ReShape Lifesciences annual EBIT year-on-year change?
  • What is ReShape Lifesciences quarterly earnings before interest & taxes?
  • What is the all time high quarterly EBIT for ReShape Lifesciences?
  • What is ReShape Lifesciences quarterly EBIT year-on-year change?
  • What is ReShape Lifesciences TTM earnings before interest & taxes?
  • What is the all time high TTM EBIT for ReShape Lifesciences?
  • What is ReShape Lifesciences TTM EBIT year-on-year change?

What is ReShape Lifesciences annual earnings before interest & taxes?

The current annual EBIT of RSLS is -$14.64 M

What is the all time high annual EBIT for ReShape Lifesciences?

ReShape Lifesciences all-time high annual earnings before interest & taxes is -$1.90 M

What is ReShape Lifesciences annual EBIT year-on-year change?

Over the past year, RSLS annual earnings before interest & taxes has changed by +$12.44 M (+45.94%)

What is ReShape Lifesciences quarterly earnings before interest & taxes?

The current quarterly EBIT of RSLS is -$1.76 M

What is the all time high quarterly EBIT for ReShape Lifesciences?

ReShape Lifesciences all-time high quarterly earnings before interest & taxes is -$1.76 M

What is ReShape Lifesciences quarterly EBIT year-on-year change?

Over the past year, RSLS quarterly earnings before interest & taxes has changed by +$1.34 M (+43.25%)

What is ReShape Lifesciences TTM earnings before interest & taxes?

The current TTM EBIT of RSLS is -$7.92 M

What is the all time high TTM EBIT for ReShape Lifesciences?

ReShape Lifesciences all-time high TTM earnings before interest & taxes is -$2.80 M

What is ReShape Lifesciences TTM EBIT year-on-year change?

Over the past year, RSLS TTM earnings before interest & taxes has changed by +$10.05 M (+55.94%)